Geron Corp (OQ:GERN)

Mar 19, 2024 09:07 am ET
Geron Corporation Announces Pricing of $150 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the pricing of an underwritten offering consisting of 41,999,998 shares of its common stock at a price of $3.00 per share and pre-funded warrants to purchase 8,002,668 shares of its common stock. The pre-funded warrants are being sold at a price of $2.999 per pre-funded warrant. All of the securities in the offering are to be sold by Geron. The offering included participation from RA Capital Management, Fairmount, OrbiMed, Farallon Capital Management, Adage Capital Partners, L.P., Boxer Capital,
Mar 14, 2024 03:54 pm ET
Geron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk M
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today announced that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 12 to 2 in favor of the clinical benefit/risk profile of imetelstat for the treatment of transfusion-dependent (TD) anemia in adult patients with low-to-intermediate-1 risk myelodysplastic syndromes (LR-MDS) who have not responded to or have lost response to or are ineligible for erythropoiesi
Feb 28, 2024 07:05 am ET
Geron Corporation Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported business highlights and financial results for the fourth quarter and full year 2023.
Feb 22, 2024 04:30 pm ET
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 397,010 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.
Feb 14, 2024 04:30 pm ET
Geron to Announce Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it will release its fourth quarter and full-year 2023 financial results and business highlights before the market opens on Wednesday, February 28, 2024 via press release, which will be available on the Company’s website at www.geron.com/
Jan 18, 2024 04:30 pm ET
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 895,930 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.
Jan 12, 2024 08:30 am ET
Geron to Participate in the B. Riley Securities Virtual Oncology Conference
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to participate in a fireside chat at the B. Riley Securities Virtual Oncology Conference on Thursday, January 18th, 2024, at 10:30am ET.
Dec 21, 2023 04:30 pm ET
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 417,490 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.
Dec 11, 2023 04:15 pm ET
Geron Announces IMerge Phase 3 Presentations at ASH Highlighting Significant Durability of Transfusion Independence and Breadth of Effect Across MDS Subgroups with Imetelstat in Lower Risk MDS
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced presentations of data from its IMerge Phase 3 clinical trial evaluating first-in-class investigational telomerase inhibitor imetelstat in patients with lower risk myelodysplastic syndromes (MDS), as well as population analysis of claims data in lower risk MDS. The data were presented at the American Society of Hematology (ASH) Annual Meeting, taking place from December 9-12, 2023, in San Diego, CA and virtually as well as published online in Blood.
Dec 06, 2023 08:00 am ET
Geron Announces Fifty Percent Enrollment in the Phase 3 IMpactMF Clinical Trial Evaluating Imetelstat in Patients with Relapsed/Refractory Myelofibrosis
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced achievement of fifty percent enrollment in the Phase 3 IMpactMF clinical trial investigating the Company’s first-in-class telomerase inhibitor, imetelstat, versus best available therapy (BAT) in patients with relapsed/refractory myelofibrosis (MF).
Dec 04, 2023 05:00 am ET
Geron Announces Publication in The Lancet of Results from the IMerge Phase 3 Clinical Trial Evaluating Imetelstat in Lower Risk MDS
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced publication in The Lancet of results from the IMerge Phase 3 trial investigating imetelstat versus placebo in patients with lower risk myelodysplastic syndromes (MDS) relapsed/refractory or ineligible for erythropoiesis stimulating agents (ESAs). The publication is available online and will be available in print at a later date.
Nov 28, 2023 08:00 am ET
Geron Corporation Announces Appointment of Gaurav Aggarwal, M.D., to its Board of Directors
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the appointment of Gaurav Aggarwal, M.D., to the Company’s Board of Directors. Dr. Aggarwal has been a prominent investor in the life sciences sector for more than two decades and has a history of expertise in financial and corporate strategy, as well as business development, in companies with which he has been affiliated at both an operational and board level.
Nov 16, 2023 04:30 pm ET
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 438,950 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.
Nov 07, 2023 04:30 pm ET
Geron to Participate at Upcoming Investor Conferences in November
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to present at the following investor conferences:
Nov 02, 2023 09:00 am ET
Geron IMerge Phase 3 Presentations at Upcoming ASH Annual Meeting Reinforce Significant Durability and Breadth of Effect of Imetelstat in Lower Risk MDS
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the publication of abstracts from the IMerge Phase 3 clinical trial evaluating its first-in-class investigational telomerase inhibitor imetelstat in patients with lower risk myelodysplastic syndromes (MDS). Four abstracts have been accepted for presentation at the 65th American Society of Hematology (ASH) Annual Meeting taking place from December 9-12 in San Diego, California and virtually.
Nov 02, 2023 08:00 am ET
Geron Corporation Reports Business Highlights and Third Quarter 2023 Financial Results
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported business highlights and financial results for the third quarter of 2023.
Oct 26, 2023 04:30 pm ET
Geron to Announce Third Quarter 2023 Financial Results on November 2, 2023
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it will release its third quarter 2023 financial results and business highlights before the market opens on Thursday, November 2, 2023 via press release, which will be available on the Company’s website at www.geron.com/investors. Ge
Oct 19, 2023 04:30 pm ET
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 401,220 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.
Sep 29, 2023 08:00 am ET
Geron Announces EMA Validation of Marketing Authorization Application for Imetelstat for the Treatment of Lower Risk MDS
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for imetelstat, a first-in-class investigational telomerase inhibitor, for the treatment of transfusion-dependent anemia in patients with lower risk myelodysplastic syndromes (MDS). The MAA was submitted earlier this month and is now under regulatory review by the European Committee for Medicinal Products for Human Use (CHMP) under the centralized procedure, which applies to all 27 EU member state
Sep 11, 2023 04:30 pm ET
Geron Announces Appointment of Michelle Robertson as Executive Vice President, Chief Financial Officer and Treasurer, and the Retirement of Olivia Bloom, Geron's Long-Time Chief Financial Officer
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the appointment of Michelle Robertson as Executive Vice President, Chief Financial Officer (CFO) and Treasurer, effective September 25, 2023. Ms. Robertson's appointment follows the retirement of Olivia Bloom, Geron's incumbent CFO, also effective September 25, 2023. Ms. Bloom's retirement brings to a close a remarkable career of nearly 30 years on Geron’s finance team, including serving the last twelve years as CFO.
Sep 07, 2023 08:00 am ET
Geron Announces Data Presentations from IMerge Phase 3 Evaluating Imetelstat in Lower Risk MDS at Society of Hematologic Oncology Annual Meeting
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced poster presentations of data from IMerge, the Company’s Phase 3 clinical trial evaluating its first-in-class investigational telomerase inhibitor imetelstat vs. placebo in patients with lower risk myelodysplastic syndromes (MDS) at the eleventh annual Society of Hematologic Oncology Annual Meeting (SOHO) held in Houston, Texas and virtually.
Sep 05, 2023 04:30 pm ET
Geron to Participate in the Baird 2023 Global Healthcare Conference
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to participate in a fireside chat in person at the Baird 2023 Global Healthcare Conference in New York City, NY, on Tuesday, September 12, 2023, at 4:55 p.m. ET.
Aug 22, 2023 08:00 am ET
Geron Announces PDUFA Date for Imetelstat NDA in Lower Risk MDS
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that the United States Food and Drug Administration (FDA) has assigned a standard review and a Prescription Drug User Fee Act (PDUFA) action date of June 16, 2024 for Geron’s New Drug Application (NDA) for imetelstat for the treatment of transfusion-dependent anemia in patients with lower risk myelodysplastic syndromes (MDS). In addition, the FDA informed the Company that it is currently planning to hold an advisory committee meeting as part of the NDA review.
Aug 21, 2023 08:00 am ET
Geron Announces FDA Acceptance of New Drug Application for Imetelstat for the Treatment of Lower Risk MDS
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that the United States Food and Drug Administration (FDA) has accepted the filing of Geron’s New Drug Application (NDA) for imetelstat, its first-in-class telomerase inhibitor, for the treatment of transfusion-dependent anemia in patients with lower risk myelodysplastic syndromes (MDS).
Aug 17, 2023 04:30 pm ET
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 189,850 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.
Aug 03, 2023 04:05 pm ET
Geron Corporation Reports Business Highlights and Second Quarter 2023 Financial Results
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported business highlights and financial results for the second quarter of 2023.
Jul 27, 2023 04:30 pm ET
Geron to Announce Second Quarter 2023 Financial Results on August 3, 2023
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it will release its second quarter 2023 financial results on Thursday, August 3, 2023 at 4:00 p.m. Eastern Time via press release, which will be available on the Company’s website at www.geron.com/investors. Geron will host a confere
Jul 20, 2023 04:30 pm ET
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 130,050 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.
Jun 29, 2023 08:30 am ET
Geron Announces U.S. Expanded Access Protocol for Imetelstat in Lower Risk MDS
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that an Expanded Access Protocol (EAP) is available for imetelstat, the Company’s first-in-class telomerase inhibitor. As allowed under the U.S. Food and Drug Administration (FDA) policies, companies may offer an EAP, which permits an investigational medicinal product intended to treat a serious or life-threatening condition, such as lower risk myelodysplastic syndromes (MDS), to be used outside of a clinical trial.1
Jun 22, 2023 04:30 pm ET
Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 72,770 shares of Geron common stock as inducements to a newly hired employee in connection with commencement of employment with the Company.
Jun 20, 2023 09:00 am ET
Geron Announces Submission of New Drug Application to FDA for First-in-Class Telomerase Inhibitor Imetelstat
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the submission to the United States Food and Drug Administration (FDA) of a New Drug Application (NDA) for imetelstat for the treatment of transfusion-dependent anemia in adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) who have failed to respond or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs).
Jun 13, 2023 09:00 am ET
Geron Announces First Patient Dosed in Investigator-Led Phase 2 IMpress Trial Evaluating Imetelstat in Patients with Relapsed/Refractory AML or Higher Risk MDS
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that the first patient has been dosed in the investigator-led Phase 2 IMpress clinical trial evaluating imetelstat, the Company’s first-in-class telomerase inhibitor, in patients with acute myeloid leukemia (AM)L, or higher risk myelodysplastic syndromes (MDS), who are relapsed/refractory/intolerant to hypomethylating agents (HMAs).
Jun 12, 2023 08:00 am ET
Geron Announces New Data and Analyses from IMerge Phase 3 Presented at EHA Reporting Robust Durability of Transfusion Independence, Evidence of Disease-Modifying Activity and Favorable Fatigue PRO in
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced new data and analyses from IMerge Phase 3 reporting robust durability of transfusion independence (TI), evidence for disease-modifying activity and favorable fatigue patient-reported outcomes (PRO) in lower risk myelodysplastic syndromes (MDS) patients treated with the Company’s first-in-class telomerase inhibitor, imetelstat, vs. placebo. The data and analyses were presented at the European Hematology Association (EHA) Annual Meeting, which took place from June 8-11, 2023 in Frankfurt, Germany a
Jun 07, 2023 04:30 pm ET
Geron to Participate in Goldman Sachs 44th Annual Global Healthcare Conference
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to participate in a fireside chat in person at the Goldman Sachs 44th Annual Global Healthcare Conference in Dana Point, CA, on Thursday, June 15, 2023 at 8:40 a.m. PT.
Jun 06, 2023 04:30 pm ET
Geron to Host Virtual Investor Event on June 14, 2023
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, will host a virtual investor event on Wednesday, June 14, 2023 at 8:00 a.m. Eastern Time.
Jun 05, 2023 10:50 am ET
Thinking about buying stock in SoFi Technologies, ImmunoGen, Equitrans Midstream, Geron, or Microvision?
NEW YORK, June 5, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SOFI, IMGN, ETRN, GERN, and MVIS.
Jun 02, 2023 03:30 pm ET
Geron Announces ASCO Presentation Reporting Durable Continuous Transfusion Independence with Imetelstat in IMerge Phase 3 Lower Risk MDS Patients
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, announced a presentation reporting durable continuous transfusion independence with imetelstat, the Company’s first-in-class telomerase inhibitor, in IMerge Phase 3 lower risk MDS patients. These data were presented today at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL.
May 31, 2023 10:55 am ET
May 25, 2023 05:02 pm ET
Geron Oral Presentation at Upcoming ASCO Annual Meeting to Highlight Meaningful Continuous Transfusion Independence Observed in Imetelstat-Treated Lower Risk MDS Patients in IMerge Phase 3
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced acceptance of its IMerge Phase 3 abstract as an oral presentation at the upcoming 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. This abstract describes statistically significant positive efficacy and safety data from the pivotal IMerge Phase 3 clinical trial evaluating the Company’s first-in-class telomerase inhibitor, imetelstat, in lower risk myelodysplastic syndromes (MDS). These data support the Company’s planned New Drug Application (NDA) submission to the U.S. FDA which
May 18, 2023 04:30 pm ET
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 128,840 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.
May 11, 2023 10:02 am ET
Geron Presentations at Upcoming EHA Annual Meeting to Report Updated Durability, Disease Modification and Favorable Patient Reported Outcomes (PRO) in Imetelstat-Treated Lower Risk MDS Patients in IMe
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that five abstracts related to imetelstat, a first-in-class telomerase inhibitor, have been accepted at the European Hematology Association (EHA) Annual Meeting taking place from June 8-11, 2023 in Frankfurt, Germany and virtually. The three EHA abstracts on IMerge Phase 3 data expand upon and further confirm the differentiating qualities of imetelstat that can address current unmet needs for lower risk MDS patients compared to available treatments. In addition, abstracts submitted by Geron colla
May 11, 2023 08:00 am ET
Geron Corporation Reports First Quarter 2023 Financial Results and Business Highlights
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported business updates and financial results for the first quarter of 2023.
May 04, 2023 04:30 pm ET
Geron to Announce First Quarter 2023 Financial Results on May 11, 2023
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it will release its first quarter 2023 financial results on Thursday, May 11, 2023 at 8:00 a.m. Eastern Time via press release, which will be available on the Company’s website at www.geron.com/investors. Geron will host a conference
May 01, 2023 02:07 pm ET
GERON CORPORATION (NASDAQ: GERN) INVESTOR UPDATE: NOTICE OF NEW DEADLINE TO FILE CLAIM OR REQUEST TO BE EXCLUDED FROM THE CLASS; Important Claims Filing Deadline in Proposed Settlement in the Geron Se
UNITED STATES DISTRICT COURTNORTHERN DISTRICT OF CALIFORNIA JULIA JUNGE and RICHARD JUNGE, on behalf of themselves and a class of similarly situated investors, Plaintiffs, v. GERON CORPORATION and JOHN A. SCARLETT, Defendants.Case No.:...
Apr 26, 2023 10:05 am ET
Geron Announces Upcoming Oral Presentation at 2023 American Society of Clinical Oncology Annual Meeting of Imetelstat Data from IMerge Phase 3 Lower Risk MDS Trial
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that data from the pivotal IMerge Phase 3 clinical trial evaluating the Company’s first-in-class telomerase inhibitor, imetelstat, in lower risk myelodysplastic syndromes (MDS), was accepted for oral presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. The data in the ASCO abstract will be embargoed per ASCO guidelines until May 25, 2023 at 5 p.m. Eastern Time. ASCO is taking place in Chicago, IL from June 2-6, 2023.
Apr 20, 2023 04:30 pm ET
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 1,684,220 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.
Apr 12, 2023 04:40 pm ET
Geron to Present at Upcoming Investor Conferences in April
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to participate in fireside chats at following investor conferences:
Mar 16, 2023 05:45 pm ET
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 490,630 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.
Mar 16, 2023 04:05 pm ET
Geron Corporation Reports Fourth Quarter and Full Year 2022 Financial Results and Upcoming Milestones
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported business updates, upcoming milestones and financial results for the fourth quarter and year ended December 31, 2022.
Mar 09, 2023 04:30 pm ET
Geron to Announce Fourth Quarter and Full-Year 2022 Financial Results on March 16, 2023
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it will release its fourth quarter and full-year 2022 financial results after the market closes on Thursday, March 16, 2023 via press release, which will be available on the Company’s website at www.geron.com/investors. Geron will ho
Feb 16, 2023 04:30 pm ET
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 640,550 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.
Jan 19, 2023 04:30 pm ET
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 75,730 shares of Geron common stock as inducements to a newly hired employee in connection with commencement of employment with the Company.
Jan 16, 2023 09:32 pm ET
Kaplan Fox Announces GERON CORPORATION (NASDAQ: GERN) INVESTOR ALERT – Important Claims Filing Deadline in Proposed Settlement in the Geron Securities Litigation is February 16, 2023
UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF CALIFORNIA JULIA JUNGE and RICHARD JUNGE, on behalf ofthemselves and a class of similarly situated investors,                          Plaintiffs,           v.GERON CORPORATION and JOHN A....
Jan 12, 2023 07:30 am ET
Geron to Present at the B. Riley Securities 3rd Annual Virtual Oncology Conference
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at the B. Riley Securities 3rd Annual Virtual Oncology Conference on January 18 at 1 p.m. ET.
Jan 11, 2023 07:30 am ET
Geron Announces Experienced Commercial Leadership Hired for Planned Commercial Launch of Imetelstat in the U.S.
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today highlighted multiple additions to its senior commercial leadership team, as it prepares for the potential commercialization in the U.S. market of imetelstat, a first-in-class telomerase inhibitor. Key additions include seasoned professionals with deep operational and launch experience in Trade & Channel Relations, Market Access, Marketing, Medical Affairs and Sales. The Company recently reported positive top-line results from its IMerge Phase 3 clinical trial in lower risk myelodysplastic syndromes (MDS) a
Jan 10, 2023 04:30 pm ET
Geron Corporation Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants Plus Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Total Gross Proc
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the closing of its upsized underwritten public offering of common stock and pre-funded warrants, plus the full exercise of the underwriters’ option to purchase additional shares of common stock for total gross proceeds of $227.8 million. All of the securities in the offering were sold by Geron.
Jan 06, 2023 09:56 am ET
Thinking about buying stock in Zomedica, Nio, Geron Corp, Microsoft, or Lucid Group?
NEW YORK, Jan. 6, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ZOM, NIO, GERN, MSFT, and LCID.
Jan 05, 2023 11:15 pm ET
Geron Corporation Announces Pricing of $198 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the pricing of an upsized underwritten public offering consisting of 55,876,297 shares of its common stock at a public offering price of $2.45 per share and pre-funded warrants to purchase 25,000,000 shares of its common stock. The pre-funded warrants are being sold at a public offering price of $2.449 per pre-funded warrant. All of the securities in the offering are to be sold by Geron. In addition, Geron has granted the underwriters a 30-day option to purchase up to an additional 12,131,444 sha
Jan 04, 2023 04:19 pm ET
Geron Corporation Announces Proposed Public Offering of Common Stock
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it intends to offer and sell $175 million of shares of its common stock in an underwritten public offering. All of the securities in the proposed offering are to be sold by Geron. Geron intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of its common stock offered in the public offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed,
Jan 04, 2023 07:36 am ET
Thinking about buying stock in Geron Corp, InMed Pharmaceuticals, Kingsoft Cloud, Vivos Therapeutics, or Baozun?
NEW YORK, Jan. 4, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GERN, INM, KC, VVOS, and BZUN.
Jan 04, 2023 06:55 am ET
Geron Announces Positive Top-Line Results from IMerge Phase 3 Trial of Imetelstat in Lower Risk MDS
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced positive top-line results from its IMerge Phase 3 clinical trial evaluating the Company’s first-in-class telomerase inhibitor, imetelstat, in lower risk myelodysplastic syndromes (MDS) patients who are relapsed, refractory or ineligible for erythropoiesis stimulating agents (ESAs). The trial met its primary efficacy endpoint of 8-week TI and a key secondary endpoint of 24-week TI, demonstrating highly statistically significant and clinically meaningful benefit of imetelstat versus placebo with no
Jan 03, 2023 04:30 pm ET
Geron Announces Conference Call for Top-Line Results from IMerge Phase 3
Geron Corporation (Nasdaq: GERN) today announced that it will host a conference call to discuss top-line results from the IMerge Phase 3 clinical trial of imetelstat, the Company’s first-in-class telomerase inhibitor, in lower risk myelodysplastic syndromes (MDS) on January 4, 2023, at 8:00 a.m. ET.
Dec 22, 2022 04:30 pm ET
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 867,130 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.
Dec 12, 2022 08:00 am ET
Geron Reports Oral Presentation at ASH Annual Meeting Highlighting Continuous Long-Term Transfusion Independence with Imetelstat Treatment in Lower Risk MDS Patients
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced results from an oral presentation at the 64th American Society of Hematology (ASH) Annual Meeting on longer follow-up data from the IMerge Phase 2 clinical trial of imetelstat, the Company’s first-in-class telomerase inhibitor, in lower risk myelodysplastic syndromes (MDS). The data in the presentation focused on the patients who achieved greater than one-year sustained continuous transfusion independence and included their baseline characteristics, clinical benefits and observed safet
Nov 17, 2022 04:30 pm ET
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 566,890 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.
Nov 07, 2022 04:30 pm ET
Geron to Participate in Stifel 2022 Healthcare Conference
Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to participate in a fireside chat in person at the Stifel 2022 Healthcare Conference in New York City on Tuesday, November 15, 2022 at 10:55 a.m. ET.
Nov 03, 2022 09:01 am ET
Geron Announces Presentations at Upcoming ASH Annual Meeting Including Long-term Phase 2 Data Showing Continuous Durable Transfusion Independence in Patients with Lower Risk MDS
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that four abstracts related to imetelstat, a first-in-class telomerase inhibitor, have been accepted for presentation at the 64th American Society of Hematology (ASH) Annual Meeting taking place from December 10-13 in New Orleans, Louisiana. A fifth abstract has been published on the ASH website and will be available in Blood. These abstracts assess the potential of imetelstat in various blood cancers, or hematologic malignancies, including lower risk myelodysplastic syndromes (
Nov 03, 2022 08:00 am ET
Geron Corporation Reports Third Quarter 2022 Financial Results and Upcoming Expected Milestones
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported financial results for the third quarter of 2022 and upcoming expected milestones.
Oct 27, 2022 04:30 pm ET
Geron to Announce Third Quarter 2022 Financial Results on November 3, 2022
Geron Corporation (Nasdaq: GERN) today announced that it will release its third quarter 2022 financial results before the market opens on Thursday, November 3, 2022 via press release, which will be available on the Company’s website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well a
Oct 20, 2022 04:30 pm ET
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 843,260 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.
Sep 22, 2022 04:30 pm ET
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 901,950 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.
Sep 08, 2022 04:15 pm ET
Geron Appoints Biopharma Veteran John F. McDonald to Board of Directors
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the appointment of John F. McDonald as an independent member of its Board of Directors, effective September 7, 2022.
Sep 01, 2022 04:30 pm ET
Geron to Present at Upcoming Investor Conferences
Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to present in-person at the following investor conferences in New York City:
Aug 22, 2022 04:15 pm ET
Geron Announces First Patient Dosed in IMproveMF Phase 1 Combination Study in Frontline Myelofibrosis
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that the first patient has been dosed in IMproveMF, a Phase 1 study evaluating imetelstat, a first-in-class telomerase inhibitor, in combination with ruxolitinib in patients with frontline myelofibrosis (MF).
Aug 18, 2022 04:30 pm ET
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 365,800 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.
Aug 11, 2022 04:05 pm ET
Geron Corporation Reports Second Quarter 2022 Financial Results
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported financial results for the second quarter of 2022 and key upcoming expected milestones.
Aug 04, 2022 04:30 pm ET
Geron to Announce Second Quarter 2022 Financial Results on August 11, 2022
Geron Corporation (Nasdaq: GERN) today announced that it will release its second quarter 2022 financial results after the market closes on Thursday, August 11, 2022 via press release, which will be available on the Company’s website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well a
Aug 03, 2022 04:30 pm ET
Geron to Participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference
Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, plans to participate in a fireside chat at the 2022 Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 10, 2022 at 12:35 p.m. ET.
Jul 21, 2022 07:05 pm ET
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 405,800 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.
Jun 30, 2022 04:15 pm ET
Geron Corporation Announces Expansion of Existing Loan Facility
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced an amendment to expand its existing loan facility with Hercules Capital, Inc. (NYSE: HTGC) and Silicon Valley Bank, from up to $75 million to up to $125 million.
Jun 16, 2022 04:30 pm ET
Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation (Nasdaq: GERN) today reported that it has granted a non-statutory stock option to purchase an aggregate of 70,000 shares of Geron common stock as an inducement to a newly hired employee in connection with commencement of employment with the Company.
Jun 15, 2022 04:10 pm ET
Geron Corporation Announces Appointment of Faye Feller, M.D. to Chief Medical Officer and Transition of Aleksandra Rizo, M.D., Ph.D. to Senior Advisor Role
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the appointment of Faye Feller, M.D., to Executive Vice President and Chief Medical Officer, effective July 9, 2022. Dr. Feller will succeed Dr. Aleksandra Rizo, Geronʻs current Chief Medical Officer, who will transition to a consultant role to the Company, as Senior Medical and Regulatory Advisor. Outside of Geron, Dr. Rizo has accepted a leadership position with a privately held discovery and preclinical-stage platform biotechnology company.
May 19, 2022 04:30 pm ET
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 327,400 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.
May 17, 2022 04:30 pm ET
Geron to Present at the H.C. Wainwright Global Investment Conference
Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, plans to present a company overview at the H.C. Wainwright Global Investment Conference. The presentation will be available as an on-demand session beginning May 24, 2022 at 7 a.m. ET.
May 09, 2022 04:05 pm ET
Geron Corporation Reports First Quarter 2022 Financial Results
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported financial results for the first quarter of 2022, including current and projected financial resources.
May 02, 2022 04:30 pm ET
Geron to Announce First Quarter 2022 Financial Results on May 9, 2022
Geron Corporation (Nasdaq: GERN) today announced that it will release its first quarter 2022 financial results after the market closes on Monday, May 9, 2022 via press release, which will be available on the Company’s website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well as recen
Apr 21, 2022 04:30 pm ET
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 505,800 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.
Apr 06, 2022 04:30 pm ET
Geron to Present at the 21st Annual Needham Virtual Healthcare Conference
Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, plans to present a company overview at the 21st Annual Needham Virtual Healthcare Conference on Wednesday, April 13, 2022 at 3:45 p.m. ET.
Apr 01, 2022 04:15 pm ET
Geron Corporation Announces the Closing of its Public Offering of Common Stock and Warrants
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 53,333,334 shares of its common stock and pre-funded warrants to purchase 18,095,238 shares of common stock, together with accompanying warrants to purchase 35,714,286 shares of common stock. The combined offering price to the public of each share of common stock and accompanying warrant was $1.05. The combined offering price to the public of each pre-funded warrant and accompanying warrant was $1.049. The common stock and pr
Mar 30, 2022 02:25 am ET
Geron Corporation Announces the Pricing of its Public Offering of Common Stock and Warrants
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 53,333,334 shares of its common stock and pre-funded warrants to purchase 18,095,238 shares of its common stock, together with accompanying warrants to purchase 35,714,286 shares of its common stock. The combined offering price to the public of each share of common stock and accompanying warrant is $1.05. The combined offering price to the public of each pre-funded warrant and accompanying warrant is $1.049. The common stock
Mar 29, 2022 04:01 pm ET
Geron Corporation Announces Proposed Public Offering of Common Stock and Warrants
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it intends to offer and sell shares of its common stock, or for certain investors that so choose, in lieu of shares of its common stock, pre-funded warrants to purchase shares of its common stock, together with accompanying warrants to purchase shares of its common stock in an underwritten public offering. All of the securities in the proposed offering are to be sold by Geron. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offe
Mar 17, 2022 04:30 pm ET
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 320,000 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.
Mar 10, 2022 04:06 pm ET
Geron Corporation Reports Fourth Quarter and Full Year 2021 Financial Results and Upcoming Milestones
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported business updates, upcoming milestones and financial results for the fourth quarter and year ended December 31, 2021. The Company ended 2021 with $212.7 million in cash and marketable securities, which the Company believes is sufficient to fund current operations through the end of the first quarter of 2023.
Mar 03, 2022 04:30 pm ET
Geron to Announce Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022
Geron Corporation (Nasdaq: GERN) today announced that it will release its fourth quarter and full year 2021 financial results after the market closes on Thursday, March 10, 2022 via press release, which will be available on the Company’s website at www.geron.com/investors. Geron will host a conference call to discuss the financial resu
Jan 21, 2022 07:30 am ET
Geron to Present at the B. Riley Securities Virtual Oncology Investor Conference
Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, will participate in a fireside chat at the B. Riley Securities Virtual Oncology Investor Conference on Friday, January 28, 2022 at 11:00 a.m. ET.
Jan 20, 2022 04:30 pm ET
Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 435,800 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.
Jan 04, 2022 05:01 pm ET
Geron to Present at the H.C. Wainwright BioConnect Conference
Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, will present a company overview at the H.C. Wainwright BioConnect Conference.
Dec 16, 2021 04:30 pm ET
Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation (Nasdaq: GERN) today reported that it has granted a non-statutory stock option to purchase an aggregate of 50,000 shares of Geron common stock as an inducement to a newly hired employee in connection with commencement of employment with the Company.
Dec 14, 2021 04:30 pm ET
Geron Reports Presentations at American Society of Hematology Annual Meeting
Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced three poster presentations related to imetelstat, the Company’s first in class telomerase inhibitor, at the 63rd American Society of Hematology (ASH) Annual Meeting. The posters are available at
Dec 02, 2021 07:30 am ET
Geron Announces Appointment of Chief Business Officer
Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced the appointment of Edward Koval as Executive Vice President and Chief Business Officer.
Nov 18, 2021 04:30 pm ET
Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation (Nasdaq: GERN) today reported that it has granted a non-statutory stock option to purchase an aggregate of 80,000 shares of Geron common stock as an inducement to a newly hired employee in connection with commencement of employment with the Company.
Nov 12, 2021 07:30 am ET
Geron to Present at the Stifel 2021 Virtual Healthcare Conference
Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, will present a company overview at the Stifel 2021 Virtual Healthcare Conference on Tuesday, November 16, 2021 at 2:40 p.m. ET.
Nov 09, 2021 06:00 pm ET
Geron Presents Investor Event Highlights
Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, summarized key highlights from its Investor Event held on November 9. An archive of the presentation webcast is available through the Investor Relations section of Geron’s website under Events. The Company also reported its financial results for the third quarter and year to date 2021 periods. As of September 30, 2021, the Company had $215.8 million in cash and marketable securities. These financial resources, combined with expect
Nov 04, 2021 09:12 am ET
Geron Announces Imetelstat Presentations at Upcoming American Society of Hematology Annual Meeting
Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced that three abstracts related to imetelstat, the Company’s first-in-class telomerase inhibitor, have been accepted as poster presentations at the 63rd American Society of Hematology (ASH) Annual Meeting to be held from December 11-14, 2021. The abstracts are available on the ASH website at
Oct 25, 2021 04:30 pm ET
Geron Enters New Innovative Licensing and Access Pathway in the United Kingdom for Imetelstat
Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced that imetelstat, the Company’s first in class telomerase inhibitor, has been granted an Innovation Passport, which is the first prescribed entry point to the Innovative Licensing and Access Pathway (ILAP) launched in the United Kingdom (UK) by the Medicines and Healthcare products Regulatory Agency (MHRA) in January 2021, post-Brexit. The objective of this new licensing and access pathway is to reduce the time to m
Oct 21, 2021 04:30 pm ET
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 80,000 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.
Oct 18, 2021 07:30 am ET
Geron Announces Completion of Patient Enrollment in IMerge Phase 3 Clinical Trial in Lower Risk Myelodysplastic Syndromes
Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced the completion of patient enrollment in the IMerge Phase 3 clinical trial to evaluate imetelstat, a first-in-class telomerase inhibitor, in lower risk myelodysplastic syndromes (MDS). Based upon current planning assumptions, Geron expects top-line results for IMerge Phase 3 to be available at the beginning of January 2023.
Oct 15, 2021 04:05 pm ET
Geron to Host a Virtual Investor Event in November
Geron Corporation (Nasdaq: GERN) will host a virtual investor event on November 9 at 4:00 p.m. ET. Topics to be covered at the event, include:
Oct 11, 2021 04:30 pm ET
Geron Announces Publication of Analyses Comparing Real World Data to IMbark Phase 2 in Annals of Hematology
Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced the publication in the Annals of Hematology of a paper entitled “Favorable Overall Survival with Imetelstat in Relapsed/Refractory Myelofibrosis Patients Compared with Real World Data,” which details statistical analyses comparing data from the Company’s IMbark Phase 2 clinical trial to closely matched Real World Data (RWD).
Sep 16, 2021 04:30 pm ET
Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation (Nasdaq: GERN) today reported that it has granted a non-statutory stock option to purchase an aggregate of 400,000 shares of Geron common stock as an inducement to a newly hired employee in connection with commencement of employment with the Company.
Sep 01, 2021 04:30 pm ET
Geron Announces September Investor Conference Presentation Webcasts
Geron Corporation (Nasdaq: GERN) today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to present at the following investor conferences:
Aug 19, 2021 04:30 pm ET
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 550,000 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.
Aug 16, 2021 04:06 pm ET
Geron Corporation Reports Greater Than 90% Enrollment in IMerge Phase 3 and Expected Top-Line Results Accelerated to First Quarter of 2023
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported updates on the IMerge Phase 3 trial in lower risk MDS and financial results for the second quarter ended June 30, 2021. The Company will host a conference call today at 4:30 p.m. ET to discuss these updates and current events. As of June 30, 2021, the Company had $239.1 million in cash and marketable securities. These financial resources, combined with expected future non-dilutive funding under the current debt facility, are expected to fund operations through the end of the first quarter of 2023.
Aug 05, 2021 04:30 pm ET
Geron to Announce Second Quarter 2021 Financial Results on August 16, 2021
Geron Corporation (Nasdaq: GERN) today announced that it will release its second quarter and year to date 2021 financial results after the market closes on Monday, August 16, 2021 via press release, which will be available on the Company’s website at www.geron.com/investors. Geron will host a conference call to discuss the financial re
Jul 22, 2021 04:45 pm ET
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 130,000 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.
Jun 22, 2021 10:45 am ET
Thinking about buying stock in ContextLogic, Adial Pharmaceuticals, Geron Corp, Orphazyme, or Citius Pharmaceuticals?
NEW YORK, June 22, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for WISH, ADIL, GERN, ORPH, and CTXR.
Jun 21, 2021 10:55 am ET
Thinking about buying stock in Geron Corp, Ashford Hospitality Trust, Paratek Pharmaceuticals, Seanergy Maritime, or TAL Education?
NEW YORK, June 21, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GERN, AHT, PRTK, SHIP, and TAL.
Jun 18, 2021 08:30 am ET
Thinking about buying stock in Geron Corp, Vaxart, Orphazyme, Athira Pharma, or TAL Education?
NEW YORK, June 18, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GERN, VXRT, ORPH, ATHA, and TAL.
Jun 17, 2021 04:30 pm ET
Geron Announces Publication of IMbark Phase 2 Data in Journal of Clinical Oncology
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the publication of data from the IMbark Phase 2 clinical trial in the Journal of Clinical Oncology in a paper entitled, “Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis.” The publication highlights the clinical benefits observed in the study, including symptom response and overall survival, as well as the evidence of disease-modifying activity from biomarker and bone marrow fibrosis assessments.
Jun 14, 2021 04:30 pm ET
Geron Reports Two Presentations at Virtual European Hematology Association Annual Congress
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that two poster presentations of new clinical data and analyses related to imetelstat, the Company’s first-in-class telomerase inhibitor, are now available on Geron’s website as well as to participants of the EHA2021 Virtual Congress.
May 12, 2021 10:56 am ET
Geron Announces Two Presentations at Upcoming European Hematology Association Annual Congress
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that two poster presentations of new clinical data and analyses related to imetelstat, the Company’s first-in-class telomerase inhibitor, will be made at the European Hematology Association (EHA) Annual Congress meeting to be held virtually from June 9 - 17. The abstracts for the posters are available on the EHA website at
May 10, 2021 04:05 pm ET
Geron Corporation Reports First Quarter 2021 Financial Results and Recent Highlights
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, to treat hematologic myeloid malignancies, today reported financial results for the first quarter ended March 31, 2021, as well as company highlights and upcoming events. As of March 31, 2021, the Company had $244.7 million in cash and marketable securities, which is expected to fund operations until the end of 2022.
May 03, 2021 04:30 pm ET
Geron to Announce First Quarter 2021 Financial Results on May 10, 2021
Geron Corporation (Nasdaq: GERN) today announced that it will release its first quarter 2021 financial results after the market closes on Monday, May 10, 2021 via press release, which will be available on the Company’s website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well as rece
Apr 27, 2021 04:36 am ET
SHAREHOLDER ALERT: Barr Law Group Investigating GERN, MIE, CG, and EVF; Shareholders are Encouraged to Contact the Firm
National law firm Barr Law Group is investigating the actions of the officers and board of directors of Geron Corporation, Cohen & Steers MLP Income and Energy Opportunity Fund, Inc., The Carlyle Group Inc., and Eaton Vance Senior Income Trust....
Apr 22, 2021 04:30 pm ET
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 220,000 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.
Apr 20, 2021 04:00 pm ET
GERON CORPORATION INVESTOR ALERT: Geron Investors Who Have Held Their Stock Continuously Since At Least March 2018 Encouraged To Contact Kehoe Law Firm, P.C.
Kehoe Law Firm, P.C. is investigating whether certain officers and/or directors of Geron Corporation (“Geron”) (NASDAQ: GERN) breached their fiduciary duties to Geron and the Company’s shareholders. The investigation concerns whether certain...
Apr 18, 2021 08:00 am ET
Lifshitz Law Firm, P.C. Announces Investigations of Geron Corp. (NasdaqGS: GERN), Jeld-Wen Holding, Inc. (NYSE: JELD), and Oracle Corporation (NYSE: ORCL)
Geron Corp. (NasdaqGS: GERN) Lifshitz Law Firm, P.C. announces that on April 12, 2021, the Court issued an Order granting in part and denying in part Defendants' Motion to Dismiss a putative class action complaint that alleges that throughout the...
Apr 13, 2021 07:30 am ET
Geron Announces First Patient Dosed in IMpactMF Phase 3 Clinical Trial in Refractory Myelofibrosis
Geron Corporation (Nasdaq: GERN) today announced that the first patient has been dosed in IMpactMF, the Phase 3 clinical trial evaluating imetelstat, a first-in-class telomerase inhibitor, in refractory myelofibrosis (MF).
Mar 18, 2021 04:45 pm ET
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 240,000 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.
Mar 11, 2021 04:10 pm ET
Geron Corporation Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, to treat hematologic myeloid malignancies, today reported financial results for the fourth quarter and year ended December 31, 2020. The Company ended fiscal year 2020 with $260 million in cash and marketable securities, which is expected to fund operations until the end of 2022.
Mar 01, 2021 04:45 pm ET
Geron to Announce Fourth Quarter and Full Year 2020 Financial Results on March 11, 2021
Geron Corporation (Nasdaq: GERN) today announced that it will release its fourth quarter and full year 2020 financial results after the market closes on Thursday, March 11, 2021 via press release, which will be available on the Company’s website at www.geron.com/investors. Geron will host a conference call to discuss the financial resu
Feb 18, 2021 04:45 pm ET
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 431,600 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.
Jan 21, 2021 04:45 pm ET
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 120,000 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.
Jan 14, 2021 04:45 pm ET
Geron to Present at the B. Riley Securities Virtual Oncology Investor Conference
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, will present a company overview at the B. Riley Securities Virtual Oncology Investor Conference on Wednesday, January 20, at 3:00 p.m. ET.
Dec 11, 2020 08:30 am ET
Geron Announces Opening of IMpactMF Phase 3 Clinical Trial in Refractory Myelofibrosis
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the opening for patient screening and enrollment of the IMpactMF Phase 3 clinical trial of imetelstat, a first-in-class telomerase inhibitor, in refractory myelofibrosis (MF).
Dec 10, 2020 08:30 am ET
Geron Announces Fifty Percent Enrollment Milestone in IMerge Phase 3 Clinical Trial in Lower Risk MDS
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced achievement of fifty percent enrollment in the IMerge Phase 3 clinical trial of imetelstat in lower risk myelodysplastic syndromes (MDS). Data from the
Dec 07, 2020 06:45 pm ET
Geron Reports Ten Imetelstat Presentations at American Society of Hematology Annual Meeting
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that four oral presentations and six poster presentations containing clinical data and analyses related to imetelstat, the Company’s first-in-class telomerase inhibitor, were presented at the 62nd American Society of Hematology (ASH) Annual Meeting. The presentations are available at
Dec 07, 2020 04:30 pm ET
Geron Reports Ten Imetelstat Presentations at American Society of Hematology Annual Meeting
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that four oral presentations and six poster presentations containing clinical data and analyses related to imetelstat, the Company’s first-in-class telomerase inhibitor, were presented at the 62nd American Society of Hematology (ASH) Annual Meeting. The presentations are available at
Nov 19, 2020 04:30 pm ET
Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation (Nasdaq: GERN) today reported that it has granted a non-statutory stock option to purchase an aggregate of 80,000 shares of Geron common stock as an inducement to a newly-hired employee in connection with commencement of employment with the Company.
Nov 10, 2020 04:30 pm ET
Geron to Present at the Stifel Virtual Healthcare Conference
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, will present a company overview at the Stifel Virtual Healthcare Conference on Tuesday, November 17, 2020 at 2:40 p.m. ET.
Nov 05, 2020 04:05 pm ET
Geron Corporation Reports Third Quarter 2020 Financial Results and Current Events
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2020. The Company will host a conference call today at 4:30 p.m. ET to discuss third...
Nov 04, 2020 04:27 pm ET
Geron Announces Ten Imetelstat Presentations at Upcoming American Society of Hematology Annual Meeting
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that ten abstracts containing clinical data and analyses related to imetelstat, the Company’s first-in-class telomerase inhibitor, have been accepted for presentation at the 62nd American Society of Hematology (ASH) Annual Meeting to be held online from December 5-8, 2020. The abstracts are available on the ASH website at
Oct 29, 2020 04:30 pm ET
Geron to Announce Third Quarter Financial Results on November 5, 2020
Geron Corporation (Nasdaq: GERN) today announced that it will release its third quarter 2020 financial results after the market closes on Thursday, November 5, 2020 via press release, which will be available on the Company’s website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well a
Oct 28, 2020 04:35 pm ET
Geron Announces Publication of IMerge Phase 2 Data in Journal of Clinical Oncology
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that data from the IMerge Phase 2 trial were published in the Journal of Clinical Oncology. The article entitled, “Imetelstat Achieves Meaningful and Durable Transfusion Independence in High-Transfusion Burden Patients with Lower Risk Myelodysplastic Syndromes Patients in a Phase 2 Study,” is available
Oct 01, 2020 04:30 pm ET
Geron Secures Loan Facility for Up to $75 Million
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it has entered into a loan facility for up to $75 million with Hercules Capital, Inc. (NYSE: HTGC) and Silicon Valley Bank (SVB). The loan facility provides the Company with access to non-dilutive financial resources to support the imetelstat development program, as well as working capital and general corporate purposes.
Sep 17, 2020 04:30 pm ET
Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation (Nasdaq: GERN) today reported that it has granted a non-statutory stock option to purchase an aggregate of 80,000 shares of Geron common stock as an inducement to a newly-hired employee in connection with commencement of employment with the Company.
Sep 09, 2020 09:00 am ET
Geron to Present at the H.C. Wainwright Global Investment Conference
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, will present a company overview at the H.C. Wainwright 22nd Annual Global Investment Conference, to be hosted in a virtual format, on Monday, September 14, 2020 at 2:30 p.m. ET.
Aug 20, 2020 04:30 pm ET
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 270,000 shares of Geron common stock as inducements to four newly-hired employees in connection with commencement of employment with the Company.
Aug 06, 2020 04:05 pm ET
Geron Corporation Reports Second Quarter 2020 Financial Results and Current Events
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2020. The Company will host a conference call today at 4:30 p.m. ET to discuss second quarter financial results and current events.
Aug 04, 2020 04:45 pm ET
Geron to Present at the BTIG Virtual Biotechnology Conference
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Tuesday, August 11, 2020 at 12:30 p.m. ET.
Jul 30, 2020 04:30 pm ET
Geron to Announce Second Quarter Financial Results on August 6, 2020
Geron Corporation (Nasdaq: GERN) today announced that it will release its second quarter 2020 financial results after the market closes on Thursday, August 6, 2020 via press release, which will be available on the Company’s website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well as
Jul 16, 2020 08:30 am ET
Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation (Nasdaq: GERN) today reported that it has granted a non-statutory stock option to purchase an aggregate of 150,000 shares of Geron common stock as an inducement to a newly-hired employee in connection with commencement of employment with the Company.
Jul 01, 2020 08:30 am ET
Geron Receives Positive Opinion from the EMA Committee for Orphan Medicinal Products for Orphan Drug Designation in the European Union for Imetelstat to Treat Myelodysplastic Syndromes
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) issued a positive opinion on the Company’s application for...
Jun 12, 2020 08:30 am ET
Geron Reports Four Imetelstat Data Presentations at Virtual Edition of the European Hematology Association (EHA) Annual Congress
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that an oral presentation and three poster presentations of new clinical data and analyses related to imetelstat, the Company’s first-in-class...
May 28, 2020 04:05 pm ET
Geron Corporation Reports First Quarter 2020 Financial Results
Geron Corporation (Nasdaq: GERN) today reported financial results for the first quarter ended March 31, 2020. The Company will host a conference call today at 4:30 p.m. ET to discuss the recently announced planned Phase 3 clinical trial in...
May 27, 2020 04:30 pm ET
Geron Corporation Announces the Closing of its Public Offering of Common Stock and Warrants
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 107,049,375 shares of its common stock and pre-funded warrants to purchase...
May 22, 2020 07:15 am ET
Geron Corporation Announces the Pricing of its Public Offering of Common Stock and Warrants
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 107,049,375 shares of its common stock and pre-funded warrants to purchase...
May 21, 2020 04:03 pm ET
Geron Corporation Announces Proposed Public Offering of Common Stock and Warrants
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of its common stock in an underwritten...
May 21, 2020 04:01 pm ET
Geron Announces Plans for Imetelstat Phase 3 Clinical Trial in Myelofibrosis and Other Updates
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced plans for a Phase 3 clinical trial in MF patients who are refractory to treatment with a janus kinase (JAK) inhibitor, including trial design and...
May 21, 2020 08:30 am ET
Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation (Nasdaq: GERN) today reported that it has granted a non-statutory stock option to purchase an aggregate of 70,000 shares of Geron common stock as an inducement to a newly-hired employee in connection with commencement of employment with the Company.
May 14, 2020 09:05 am ET
Geron Announces Four Imetelstat Presentations at the Virtual Edition of the European Hematology Association Annual Congress
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that four abstracts containing new clinical data and analyses related to imetelstat, the Company’s first-in-class telomerase inhibitor, have been accepted for presentation at the Virtual Edition of the European Hematology Association (EHA) Annual Congress to be held online from June 11-14, 2020. The abstracts are available on the EHA website at
Apr 16, 2020 08:30 am ET
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 500,000 shares of Geron common stock as inducements to two newly-hired employees in connection with commencement of employment with the Company.
Apr 08, 2020 04:30 pm ET
Geron to Present at Needham Virtual Healthcare Conference
Geron Corporation (Nasdaq: GERN) today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, is scheduled to present a company overview at the 19th Annual Needham Virtual Healthcare Conference at 10:00 a.m. ET on Wednesday,...
Apr 02, 2020 08:00 am ET
Geron Provides COVID-19 Related Business Update
Geron Corporation (Nasdaq: GERN), a late-stage clinical development biopharmaceutical company, today announced an update to information from its March 12 year-end conference call related to the impact of the COVID-19 pandemic on the Company’s...
Mar 23, 2020 10:40 am ET
MONDAY DEADLINE ALERT: The Schall Law Firm Announces it is Investigating Claims Against Geron Corporation and Encourages Investors with Losses to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Geron Corporation (“Geron” or “the Company”) (NASDAQ:
Mar 20, 2020 05:14 pm ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Geron Corporation (GERN) Investors: Application Deadline 3 Days Away, Investors with Losses Encouraged to Contact Firm
Hagens Berman urges investors in Geron Corporation (NASDAQ: GERN) who have suffered significant losses to submit their losses now to learn if they qualify to recover their investment losses. The Lead Plaintiff deadline is March 23, 2020 and certain...
Mar 19, 2020 11:00 am ET
GERN FINAL DEADLINE - Bronstein, Gewirtz & Grossman, LLC Reminds Geron Corporation Investors of Class Action and Encourages Investors to Contact the Firm
Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Geron Corporation (“Geron” or the Company”) (NASDAQ: GERN) and certain of its officers, on behalf of shareholders who purchased Geron securities between March 19, 2018 and September 26, 2018, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site:
Mar 17, 2020 10:00 am ET
GERN FINAL DEADLINE - Bronstein, Gewirtz & Grossman, LLC Reminds Geron Corporation Investors of Class Action and Encourages Investors to Contact the Firm
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Geron Corporation (“Geron” or the "Company") (NASDAQ: GERN) and certain of its officers, on behalf of shareholders who...
Mar 15, 2020 03:09 pm ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Geron Corporation (GERN) Investors: 8 Days Remain Until Application Deadline, Investors with Losses Encouraged to Contact Firm
Hagens Berman urges investors in Geron Corporation (NASDAQ: GERN) who have suffered significant losses to submit their losses now to learn if they qualify to recover their investment losses. The Lead Plaintiff deadline is March 23, 2020 and certain...
Mar 12, 2020 04:05 pm ET
Geron Corporation Reports Fourth Quarter and Full Year 2019 Financial Results and 2020 Milestones
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, to treat hematologic myeloid malignancies, today reported financial results for the fourth quarter and...
Mar 12, 2020 02:00 pm ET
GERN & CCI SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Notifies Investors of Class Actions and Encourages Investors to Contact the Firm
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Mar 11, 2020 02:36 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Qudian, Geron Corporation, Opera Limited, and Beyond Meat and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class action lawsuits have been commenced on behalf of stockholders of Qudian, Inc. (NYSE: QD), Geron Corporation (NASDAQ: GERN), Opera Limited...
Mar 09, 2020 08:00 pm ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Geron Corporation (GERN) Investors to 2 Week Deadline: Investors Who Suffered Losses Encouraged to Contact Firm
Hagens Berman urges investors in Geron Corporation (NASDAQ: GERN) who have suffered significant losses to submit their losses now to learn if they qualify to recover their investment losses. The Lead Plaintiff deadline is March 23, 2020 and certain...
Mar 09, 2020 05:03 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Geron Corporation of Class Action Lawsuit and Upcoming Deadline – GERN
Pomerantz LLP announce that a class action lawsuit has been filed against Geron Corporation (“Geron” or the “Company”) (NASDAQ: GERN) and certain of its officers. The class action, filed in United States District Court for the Northern District of...
Mar 09, 2020 03:00 pm ET
GERN INVESTOR ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Geron Corporation Investors of Class Action and Encourages Investors to Contact the Firm
Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Geron Corporation (“Geron” or the Company”) (NASDAQ: GERN) and certain of its officers, on behalf of shareholders who purchased Geron securities between March 19, 2018 and September 26, 2018, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site:
Mar 05, 2020 06:14 pm ET
Mar 05, 2020 04:30 pm ET
Geron to Announce Fourth Quarter and Full Year 2019 Financial Results on March 12, 2020
Geron Corporation (Nasdaq: GERN) today announced that it will release its fourth quarter and full year 2019 financial results after the market closes on Thursday, March 12, 2020 via press release, which will be available on the Company’s website at www.geron.com/investors. Geron will host a conference call to discuss the financial resu
Mar 05, 2020 10:00 am ET
QD & GERN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Shareholders With Losses Exceeding $100K of Class Action Deadlines
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Mar 04, 2020 12:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against 500.com, Portola Pharmaceuticals, Qudian, and Geron Corporation and Encourages Investors to Contact the
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class action lawsuits have been commenced on behalf of stockholders of 500.com Limited (NYSE: WBAI), Portola Pharmaceuticals (NASDAQ: PTLA),...
Mar 03, 2020 02:47 pm ET
SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Geron Corporation of Class Action Lawsuit and Upcoming Deadline – GERN
Pomerantz LLP announce that a class action lawsuit has been filed against Geron Corporation (“Geron” or the “Company”) (NASDAQ: GERN) and certain of its officers.   The class action, filed in United States District Court for the Northern District...
Mar 02, 2020 08:00 pm ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Geron Corporation (GERN) Investors Who Suffered Losses to Contact its Attorneys: Application Deadline in Three Weeks
Hagens Berman urges investors in Geron Corporation (NASDAQ: GERN) who have suffered significant losses to submit their losses now to learn if they qualify to recover their investment losses. The Lead Plaintiff deadline is March 23, 2020 and certain...
Feb 27, 2020 10:00 am ET
INVESTOR ALERT - Geron Corporation (GERN) - Bronstein, Gewirtz & Grossman, LLC Reminds Investors With Losses Exceeding $100K of Class Action and Lead Deadline: March 23, 2020
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Geron Corporation  (“Geron” or the Company”) (NASDAQ: GERN) and certain of its officers, on behalf of shareholders who...
Feb 26, 2020 12:57 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against 500.com, Portola Pharmaceuticals, Qudian, and Geron Corporation and Encourages Investors to Contact the
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class action lawsuits have been commenced on behalf of stockholders of 500.com Limited (NYSE: WBAI), Portola Pharmaceuticals (NASDAQ: PTLA),...
Feb 24, 2020 07:55 pm ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Urges Geron Corporation (GERN) Investors With Losses to Contact its Attorneys: Application Deadline Approaching
Hagens Berman urges investors in Geron Corporation (NASDAQ: GERN) who have suffered significant losses to submit their losses now to learn if they qualify to recover their investment losses. The Lead Plaintiff deadline is March 23, 2020 and certain...
Feb 24, 2020 04:19 pm ET
SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Geron Corporation of Class Action Lawsuit and Upcoming Deadline – GERN
Pomerantz LLP announce that a class action lawsuit has been filed against Geron Corporation (“Geron” or the “Company”) (NASDAQ: GERN) and certain of its officers.   The class action, filed in United States District Court for the Northern District...
Feb 20, 2020 08:00 am ET
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 100,000 shares of Geron common stock as inducements to two newly-hired employees in connection with commencement of employment with the Company.
Feb 19, 2020 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS GERN, OPRA, QD INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Qudian Inc. (QD)Class Period: 12/13/2018 - 1/15/2020Lead Plaintiff Motion Deadline: March 23,...
Feb 19, 2020 12:17 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Geron Corporation, Opera Limited, Beyond Meat, and Westpac Banking Corporation and Encourages Investors
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Geron Corporation (NASDAQ: GERN), Opera Limited (NASDAQ: OPRA), Beyond Meat,...
Feb 18, 2020 10:50 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of GERN, OPRA and QD
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. Geron Corporation (GERN)Investors Affected: March 19, 2018 - September 26, 2018Lead Plaintiff Motion Deadline:...
Feb 18, 2020 08:06 pm ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds Geron Corporation (GERN) Investors With Losses to Contact its Attorneys: Application Deadline Approaching
Hagens Berman urges investors in Geron Corporation (NASDAQ: GERN) who have suffered significant losses to submit their losses now to learn if they qualify to recover their investment losses. The Lead Plaintiff deadline is March 23, 2020 and certain...
Feb 17, 2020 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS GERN, OPRA, QD INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Opera Limited (OPRA)Class Period: 7/27/2018 -...
Feb 14, 2020 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS GERN, OPRA, QD INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Qudian Inc. (QD)Class Period: 12/13/2018 - 1/15/2020Lead Plaintiff Motion Deadline: March 23,...
Feb 14, 2020 04:08 pm ET
Pomerantz Law Firm Announces the Filing of a Class Action against Geron Corporation and Certain Officers – GERN
Pomerantz LLP announce that a class action lawsuit has been filed against Geron Corporation (“Geron” or the “Company”) (NASDAQ: GERN) and certain of its officers.   The class action, filed in United States District Court for the Northern District...
Feb 13, 2020 11:30 am ET
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Geron Corporation
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming March 23, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of Geron Corporation (“Geron” or the “Company”) (NASDAQ: GERN) investors who purchased...
Feb 13, 2020 09:32 am ET
GERON DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Geron Corporation To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Geron Corporation (“Geron” or the “Company”) (NASDAQ:GERN) of the March 23, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Feb 12, 2020 07:30 pm ET
GERON SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Gero
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until March 23, 2020 to file lead plaintiff applications in a securities class action lawsuit against Geron Corporation (NasdaqGS: GERN), if they purchased the Company’s shares between March 19, 2018 and September 26, 2018, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of California.
Feb 12, 2020 03:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Qudian, Geron Corporation, Opera Limited, and Beyond Meat and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, Qudian, Inc. (NYSE: QD), Geron Corporation (NASDAQ: GERN), Opera Limited (NASDAQ: OPRA), and Beyond Meat, Inc. (NASDAQ: BYND). Stockholders have until the deadlines...
Feb 11, 2020 09:00 am ET
GERN Investors: March 23, 2020 Filing Deadline in Class Action – Contact Lieff Cabraser
The law firm of Lieff Cabraser Heimann & Bernstein, LLP reminds investors of the upcoming deadline to move for appointment as lead plaintiff in the class action litigation on behalf of investors who purchased the common stock of Geron Corporation
Feb 11, 2020 08:30 am ET
DEADLINE ALERT for GDOT,  MHK,  GERN and OPRA: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.